Hydrogel membrane for adhesion prevention

Patent metadata

Field	Value
Publication number	US-10850011-B2
Application number	US-201916359102-A
Country	US
Kind code	B2
Filing date	Mar 20, 2019
Priority date	Dec 11, 2012
Publication date	Dec 1, 2020
Grant date	Dec 1, 2020

Abstract

A biocompatible membrane comprised of alginate and hyaluronate. The membrane may be used to prevent unwanted scarring after surgery. The tissue adherence and the rate of bioresorption of the membrane may be modified through an external stimulus comprising a sequestering agent and a viscosity modifier.

First claim

What is claimed is:

1. A kit comprising:
uncrosslinked hyaluronic acid and crosslinked alginate both included in a hydrogel film; and
a calcium chelator;
wherein (a) the alginate is crosslinked with calcium, (b) the hydrogel film is flat and includes a width, a length, and a thickness that is less than the width and the length, (c) the hydrogel film is configured so bioresorbability of the hydrogel film increases in response to applying the calcium chelator to the hydrogel film, and (d) the hydrogel film is not templated by a crystal.

2. A system comprising:
uncrosslinked hyaluronic acid and crosslinked alginate both included in a hydrogel; and
a calcium chelator;
wherein (a) the alginate is crosslinked with calcium, (b) the hydrogel is configured so bioresorbability of the hydrogel increases in response to applying the calcium chelator to the hydrogel, (c) the hydrogel is configured to leach the hyaluronic acid, and (d) the hydrogel is not templated by a crystal.

3. The system of claim 2 , wherein the calcium chelator includes at least one of citrate, EDTA, EGTA, BAPTA, a phosphate, or combinations thereof.

4. The system of claim 2 , wherein the hydrogel comprises:
a first hydrogel layer comprising the uncrosslinked hyaluronic acid and the crosslinked alginate; and
a second hydrogel layer comprising collagen and additional hyaluronic acid.

5. The system of claim 3 wherein the hydrogel comprises a therapeutic agent that includes at least one of a drug, a pharmaceutical agent, a peptide, a protein, a medicine, a hormone, a macromolecule, or combinations thereof.

6. The system of claim 5 , wherein the hydrogel is configured so the hydrogel's release rate of the therapeutic agent increases in response to applying the calcium chelator to the hydrogel.

7. The system of claim 6 , wherein the hydrogel is configured so the hydrogel's release rate for the therapeutic agent increases in response to increasing an amount of hyaluronate in the hydrogel.

8. The system of claim 7 , wherein the hydrogel is configured so mucoadhesiveness for the hydrogel increases in response to applying the calcium chelator to the hydrogel.

9. The system of claim 8 , wherein the hydrogel is configured to increase in transparency in response to applying the calcium chelator to the hydrogel.

10. The system of claim 2 including a sealed package that includes the hydrogel and the calcium chelator.

11. A system comprising:
uncrosslinked hyaluronic acid and crosslinked alginate both included in a hydrogel;
a sequestering agent;
wherein (a) the alginate is crosslinked with a multivalent cation, (b) the hydrogel is configured so its bioresorbability increases in response to applying the sequestering agent to the hydrogel, (c) the sequestering agent is configured to sequester the multivalent cation, (d) the hydrogel is configured to leach the hyaluronic acid, and (e) the hydrogel is not templated by a crystal.

12. The system of claim 11 , wherein:
the hydrogel comprises a therapeutic agent that includes at least one of a drug, a pharmaceutical agent, a peptide, a protein, a medicine, a hormone, a macromolecule, or combinations thereof;
the hydrogel is configured so a release rate for the therapeutic agent increases in response to applying the sequestering agent to the hydrogel.

13. The system of claim 12 wherein:
the hydrogel is configured so mucoadhesiveness of the hydrogel increases in response to applying the sequestering agent to the hydrogel;
the hydrogel is configured to increase in transparency in response to applying the sequestering agent to the hydrogel.

14. The system of claim 13 including a sealed package that includes the hydrogel and the sequestering agent.

15. The system of claim 11 wherein the hydrogel consists essentially of the uncrosslinked hyaluronic acid and the crosslinked alginate.

16. The system of claim 11 wherein the hyaluronic acid is entrapped within a non-templated pore of the hydrogel based on the hyaluronic acid's size as compared to the non-templated pore's size.

17. The system of claim 16 wherein the hydrogel is configured to leach the hyaluronic acid in response to exposing the hydrogel to water.

18. The system of claim 17 wherein the hydrogel is configured to leach the hyaluronic acid in response to exposing the hydrogel to water in vivo.

19. The system of claim 17 wherein:
the hydrogel is configured to leach the hyaluronic acid at a rate;
the rate is based on a ratio of the hyaluronic acid to the alginate;
in rate increases as the ratio increases.

Assignees

• Univ Texas
• Board Of Regents The Univ Of Texas

Inventors

• Schmidt Christine E
• Zawko Scott A
• Mayes Sarah M

Classifications

• A61F2/0077

  Special surfaces of prostheses, e.g. for improving ingrowth (A61F2/30767 takes precedence) · CPC title

• A61L31/145 Primary

  Hydrogels or hydrocolloids · CPC title

• C08J2305/04

  Alginic acid; Derivatives thereof · CPC title

• C08J3/075

  Macromolecular gels · CPC title

• A61L31/148

  Materials at least partially resorbable by the body · CPC title